ResearcherStony Brook UniversityNo recent work listed

Harold Bien

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-4352-1848; OpenAlex author ID A5009453750. Sources: OpenAlex.

Their work

Papers: 2 (first author 1, last author 0)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2016: 1 paper · 2017: none · 2018: none · 2019: 1 paper

Papers 2

Challenges in Ras therapeutics in pancreatic cancer. First author DOI 10.1016/j.semcancer.2017.11.015 ↗
Liposomal Irinotecan in the Treatment of Refractory Pancreatic Cancer. Co-author DOI 10.2174/1574892811666160729094415 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Minsig Choi · 1 shared paper, 2019 · strength 0.14
- Paper Challenges in Ras therapeutics in pancreatic cancer. DOI 10.1016/j.semcancer.2017.11.015 ↗
Scott Powers · 1 shared paper, 2019 · strength 0.14
- Paper Challenges in Ras therapeutics in pancreatic cancer. DOI 10.1016/j.semcancer.2017.11.015 ↗
Minsig Choi · 1 shared paper, 2016 · strength 0.10
- Paper Liposomal Irinotecan in the Treatment of Refractory Pancreatic Cancer. DOI 10.2174/1574892811666160729094415 ↗
Gerardo Guillermo Mackenzie · 1 shared paper, 2016 · strength 0.10
- Paper Liposomal Irinotecan in the Treatment of Refractory Pancreatic Cancer. DOI 10.2174/1574892811666160729094415 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.